

3070 McCann Farm Drive, Suite 101, Garnet Valley, PA 19060 Phone: (877) 494-5346, Option 1 Fax: (877) 291-9425

## **Referral Form**

Patient Demographic Information		
Patient Name:	D0	OB: MM / DD / YYYY Sex:   M
Mailing Address:		
	Relationship to Patient:	
Home Phone: Cell Phone:		
Email: Prefer		
Language Preference: ☐ English ☐ Spanish ☐ Other		
Patient Insurance Information — Attach copies of both sides of pati		☐ Check here if no insurance
Policy Holder Name: Relationship to Patient:		
Primary Insurance: ID		
Secondary Insurance:ID		
Pharmacy Plan: ID#:		
Is patient enrolled in any government, state or federally funded prescription benefit program? (Medicare, Medicaid, Medigap, VA, DOD, Tricare)?		
Prescriber Information		
First Name: Last Name:		
State License #:		
NPI #:	DEA:	
Facility Name:		
Facility Address:	City:	State: Zip:
Office Contact:	Preferred	Contact: Phone Email Fax
Office Phone: Office Fax:	Email:	
Patient Clinical Information		
Primary Diagnosis:	ICD-10:	
Primary Diagnosis:		
Primary Diagnosis:  Drug Allergies:  Patient has demonstrated at least a partial response to prior multiagent, m	ultimodality therapy including anti	
Primary Diagnosis:  Drug Allergies:  Patient has demonstrated at least a partial response to prior multiagent, m	ultimodality therapy including anti	-GD2 immunotherapy: ☐ Yes ☐ No
Primary Diagnosis:  Drug Allergies:  Patient has demonstrated at least a partial response to prior multiagent, m  Current Disease Status:   CR PR Active Disease Relapsed	ultimodality therapy including anti	-GD2 immunotherapy: ☐ Yes ☐ No umber of Relapses (if applicable):
Primary Diagnosis:  Drug Allergies:  Patient has demonstrated at least a partial response to prior multiagent, m  Current Disease Status: □ CR □ PR □ Active Disease Relapsed  Prescription	ultimodality therapy including anti I/Refractory:	-GD2 immunotherapy: ☐ Yes ☐ No umber of Relapses (if applicable): cription* (Optional - Insurance Required)
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:	-GD2 immunotherapy:  Yes No umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No  Bridge or Quick Start Pres  IWILFIN® (eflornithine) 19  Dosing Instructions:	-GD2 immunotherapy:  Yes No umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No  Bridge or Quick Start Press  IWILFIN® (eflornithine) 19  Dosing Instructions:    I authorize IWILFIN Cares to disp of IWILFIN if insurance determine referral. Bridge and Quick Start Press	-GD2 immunotherapy:  Yes No umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies atton is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No Bridge or Quick Start Pres IWILFIN® (eflornithine) 19 Dosing Instructions:  I authorize IWILFIN Cares to disp of IWILFIN if insurance determine referral. Bridge and Quick Start Pr within the labeled indication only, *The Bridge Prescription is intendee	-GD2 immunotherapy:  Yes No umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies atton is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients and is not contingent of a purchase of any kind. It to support continuation of prescribed therapy in
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No Bridge or Quick Start Press IWILFIN® (eflornithine) 19 Dosing Instructions:   I authorize IWILFIN Cares to disp of IWILFIN if insurance determine referral. Bridge and Quick Start Press within the labeled indication only, *The Bridge Prescription is intended the event of a delay in insurance ce is intended to support new to there	-GD2 immunotherapy: ☐ Yes ☐ No  umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies attion is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients and is not contingent of a purchase of any kind. It to support continuation of prescribed therapy in overage determination. The Quick Start Prescription rapy patients in the event of a coverage delay.
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No Bridge or Quick Start Press IWILFIN® (eflornithine) 19. Dosing Instructions:     I authorize IWILFIN Cares to dispose in IWILFIN if insurance determine referral. Bridge and Quick Start Pwithin the labeled indication only, *The Bridge Prescription is intended the event of a delay in insurance continued in the Iwilfing Prescription no reimbursement to any third party	-GD2 immunotherapy:
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No Bridge or Quick Start Pres IWILFIN® (eflornithine) 19. Dosing Instructions:    I authorize IWILFIN Cares to disp of IWILFIN if insurance determine referral. Bridge and Quick Start P within the labeled indication only, *The Bridge Prescription is intended the event of a delay in insurance co is intended to support new to the Neither the Bridge Prescription no	-GD2 immunotherapy:
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes No No Bridge or Quick Start Pres  IWILFIN® (eflornithine) 19 Dosing Instructions:    I authorize IWILFIN Cares to disp of IWILFIN if insurance determine referral. Bridge and Quick Start Provision in the Indect the event of a delay in insurance of is intended to support new to the Neither the Bridge Prescription no reimbursement to any third party or terminate the program at any to	-GD2 immunotherapy:  Yes No  umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies attion is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients and is not contingent of a purchase of any kind. It to support continuation of prescribed therapy in overage determination. The Quick Start Prescription apy patients in the event of a coverage delay. The Quick Start Prescription may be submitted for payers. US WorldMeds® reserves the right to modify time without notice.
Primary Diagnosis:	ultimodality therapy including anti I/Refractory:  Yes  No No Bridge or Quick Start Press  IWILFIN® (eflornithine) 19 Dosing Instructions:    I authorize IWILFIN Cares to disp of IWILFIN if insurance determine referral. Bridge and Quick Start Pr within the labeled indication only, *The Bridge Prescription is intended the event of a delay in insurance of is intended to support new to the Neither the Bridge Prescription no reimbursement to any third party or terminate the program at any to the sis my patient, and I represent that and regulations. I also certify that are	-GD2 immunotherapy:  Yes No  umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies atton is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients and is not contingent of a purchase of any kind. It to support continuation of prescribed therapy in overage determination. The Quick Start Prescription rapy patients in the event of a coverage delay.  The Quick Start Prescription may be submitted for payers. US WorldMeds® reserves the right to modify ime without notice.  It information I have provided about this my medication received from USWM, LLC
Primary Diagnosis:	In authorize IWILFIN Cares to disposition in intended the event of a delay in insurance of is intended to support new to ther Neither the Bridge Prescription is intended the event of a delay in insurance of is intended to support new to the Neither the Bridge Prescription no reimbursement to any third party or terminate the program at any the support of the indications. I also certify that are not will be used only for this patient and will be used only for the indication only for the support new to the Neither the Bridge Prescription no reimbursement to any third party or terminate the program at any third regulations. I also certify that are not will be used only for this patient and status and receipt of the indication.	-GD2 immunotherapy:  Yes No  umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies atton is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients and is not contingent of a purchase of any kind. It to support continuation of prescribed therapy in overage determination. The Quick Start Prescription apy patients in the event of a coverage delay. The Quick Start Prescription apy patients in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescrip
Primary Diagnosis:  Drug Allergies:  Patient has demonstrated at least a partial response to prior multiagent, m Current Disease Status:   CR PR Active Disease Relapsed  Prescription  IWILFIN® (eflornithine) 192mg tablets (NDC 78670-150-01)  Dosing Instructions (select one):  768 mg (four tablets) orally twice a day (>1.5 m² BSA)  576 mg (three tablets) orally twice a day (0.75 to 1.5 m² BSA)  384 mg (two tablets) orally twice a day (0.5 to <0.75 m² BSA)  192 mg (one tablet) orally twice a day (0.25 to <0.5 m² BSA)  Other  Dosing Weight (kg):  Dosing Height (cm):  BSA (m²):  Dispense: QS for 30-day supply  Refills:  Prescriber Authorization  By signing this Authorization, I certify that the person named on this form a for this patient is appropriate for this patient named on this form a for this patient is appropriate for this patient's medical condition.  I understand that US WorldMeds and companies working with US World applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information section for verification of applicant named in the Patient Information se	In authorize IWILFIN Cares to disposition in intended the event of a delay in insurance of is intended to support new to ther Neither the Bridge Prescription is intended the event of a delay in insurance of is intended to support new to the Neither the Bridge Prescription no reimbursement to any third party or terminate the program at any the support of the indications. I also certify that are not will be used only for this patient and will be used only for the indication only for the support new to the Neither the Bridge Prescription no reimbursement to any third party or terminate the program at any third regulations. I also certify that are not will be used only for this patient and status and receipt of the indication.	-GD2 immunotherapy:  Yes No  umber of Relapses (if applicable):  cription* (Optional - Insurance Required)  2 mg tablets (NDC 78670-150-01)  ense to my patient up to two (2) 30-day supplies atton is still pending after 15 days of receipt of rescriptions are at no cost to eligible patients and is not contingent of a purchase of any kind. It to support continuation of prescribed therapy in overage determination. The Quick Start Prescription apy patients in the event of a coverage delay. The Quick Start Prescription apy patients in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription in the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescription is the event of a coverage delay. The Quick Start Prescrip

USWMIWI-00175